Consistently, targeting IL8 with Repertaxin not only increased the efficacy of Fulvestrant and/or Palbociclib therapy in ER + breast cancer cells, but also restored the sensitivity to tamoxifen, as well as increased the efficacy of Fulvestrant and/or Palbociclib therapy in tamoxifen resistant cells. This evidence concerns the gene CXCL8 and breast cancer.